Invitrogen Expands Cell Products Business with $57M Purchase of CellzDirect | GenomeWeb

Invitrogen Expands Cell Products Business with $57M Purchase of CellzDirect

Jan 10, 2008

NEW YORK (GenomeWeb News) - Invitrogen said today it will buy primary cell provider CellzDirect for around $57 million in cash in an effort to expand its cellular analysis business.

CellzDirect’s human hepatocyte-based cell products and services are used in drug testing, particularly for predicting the effect of compounds on enzymatic metabolism in the liver.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Critics Say Open-Access Plan 'Goes Too Far'

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

And Gone

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

Science and the Science Committee

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

This Week in PLOS

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.